Core Insights - Company announced the completion of the first patient dosing in a Phase 1 clinical trial for HLX13, a biosimilar of ipilimumab, for the treatment of unresectable hepatocellular carcinoma (HCC) in China [1] - The trial is a multicenter, randomized, double-blind, parallel-controlled study aimed at evaluating the pharmacokinetics, safety, efficacy, and immunogenicity of HLX13 compared to the original drug YERVOY® in previously untreated advanced HCC patients [1][2] - HLX13 is also being developed for multiple indications including melanoma, renal cell carcinoma, colorectal cancer, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell carcinoma [2] - The global sales of ipilimumab are projected to be approximately $2.873 billion in 2024 [3] Group 1 - HLX13 is a biosimilar of ipilimumab, designed to enhance immune response by blocking CTLA-4, thereby targeting tumors [2] - The Phase 1 trial involves a 1:1 random allocation of participants to receive either HLX13 or YERVOY® combined with OPDIVO® treatment [1] - The primary endpoint of the trial is the area under the concentration-time curve (AUC) from dosing to 21 days post-administration [1] Group 2 - The clinical trial application for HLX13 in HCC was approved by the National Medical Products Administration in June 2023 [2] - The company has entered into a licensing agreement with Sandoz AG for the commercialization of HLX13 in the U.S. and select European regions, Japan, Australia, and Canada [2] - The sales figure for ipilimumab indicates a significant market potential for HLX13 as a biosimilar in the oncology sector [3]

Core Insights - The 2025 European Society for Medical Oncology (ESMO) annual meeting was held in Berlin, Germany, focusing on cutting-edge topics such as immunotherapy, precision medicine, and novel targeted drugs [1] Group 1: Research Achievements - A research study led by Liu Aina and Gong Wenjing from Yantai Yuhuangding Hospital was successfully selected for presentation at the conference, showcasing significant advancements in the field of immunotherapy for advanced gastric cancer [2] - The study analyzed clinical data from 49 patients who underwent immune re-challenge therapy, evaluating key metrics such as Objective Response Rate (ORR), Disease Control Rate (DCR), Progression-Free Survival (PFS), Overall Survival (OS), and ≥3 grade immune-related adverse events (irAEs) [2] - Results indicated that immune re-challenge therapy demonstrated comparable or slightly superior clinical efficacy in survival benefits, with manageable treatment toxicity, and PD-L1 expression may serve as a valuable biomarker for predicting treatment efficacy [2] Group 2: Institutional Development - Yantai Yuhuangding Hospital's oncology department emphasizes the integration of clinical practice and research, fostering academic exploration and clinical translation in oncology [3] - The selection of the research for an international conference highlights the hospital's expertise and innovative capacity in advanced gastric cancer immunotherapy, as well as the effectiveness of its graduate training programs [3] - The hospital aims to continue advancing in the field of precision oncology, exploring and optimizing treatment strategies to provide new hope for cancer patients [3]

Core Viewpoint - The Chinese stock market experienced a slight decline, with the Shanghai Composite Index closing at 4000.14 points, down 0.07% [1] Market Performance - The Shanghai Composite Index reported a trading volume of 840.47 billion yuan - The Shenzhen Component Index closed at 13240.62 points, down 0.36%, with a trading volume of 1104.57 billion yuan - The ChiNext Index ended at 3122.03 points, down 0.39%, with a trading volume of 487.83 billion yuan [1] Sector Performance - Sectors such as brokerage, automotive, coal, semiconductor, chemical, and steel saw declines - Conversely, sectors including insurance, oil, and pharmaceuticals experienced gains - Innovative drugs, immunotherapy, and brain engineering concepts were particularly active [1]

Core Insights - The article provides an overview of the latest fund net asset values, highlighting the top-performing and bottom-performing funds in the market [1] Fund Performance Summary Top 10 Funds by Net Value Growth - The top 10 funds with the highest net value growth include: 1. E Fund S&P Biotechnology RMB C: 1.5967, growth of 3.31% 2. E Fund S&P Biotechnology RMB A: 1.6184, growth of 3.31% 3. E Fund S&P Biotechnology USD A: 0.2284, growth of 3.30% 4. E Fund S&P Biotechnology USD C: 0.2253, growth of 3.30% 5. Vanguard Growth A: 1.0911, growth of 2.95% 6. Shenwan Hongyuan Medical A: 0.4952, growth of 2.95% 7. Vanguard Growth C: 1.1104, growth of 2.95% 8. Shenwan Hongyuan Medical C: 0.4867, growth of 2.94% 9. Fuguo Medical Innovation A: 1.8086, growth of 2.86% 10. Fuguo Medical Innovation C: 1.7890, growth of 2.86% [2] Bottom 10 Funds by Net Value Decline - The bottom 10 funds with the largest net value decline include: 1. Dongcai Value Start C: 0.8164, decline of 5.32% 2. Dongcai Value Start A: 0.8302, decline of 5.31% 3. HSBC Jintrust Low Carbon Pioneer A: 3.0533, decline of 4.87% 4. HSBC Jintrust Low Carbon Pioneer C: 2.9915, decline of 4.87% 5. HSBC Jintrust Research Selected Mixed: 1.0754, decline of 4.86% 6. HSBC Jintrust Core Growth A: 1.0195, decline of 4.70% 7. HSBC Jintrust Core Growth C: 0.9970, decline of 4.69% 8. Ping An Research Selected Mixed C: 0.8939, decline of 4.65% 9. Ping An Research Selected Mixed A: 0.9228, decline of 4.64% 10. HSBC Jintrust Intelligent Manufacturing Pioneer C: 2.8535, decline of 4.63% [3] Market Overview - The Shanghai Composite Index opened lower but rebounded, closing slightly down, with a trading volume of 1.96 trillion yuan and a stock performance ratio of 1758 gainers to 3563 losers [5] - Leading sectors include insurance, oil, banking, textiles, and household appliances, while the concept of immunotherapy saw a rise of over 2% [6] - Declining sectors include mineral products and electrical equipment, both dropping over 2% [7] Fund Holdings Analysis E Fund S&P Biotechnology Holdings - The fund's top holdings include: 1. CRISPR Therapeutics AG: 2.14% 2. Exelixis Inc: 1.89% 3. AbbVie Inc: 1.89% 4. Madrigal Pharmaceuticals Inc: 1.84% 5. Moderna Inc: 1.83% - The fund has a concentration of 18.47% in its top ten holdings, focusing on the pharmaceutical sector, and has outperformed the market [8] Dongcai Value Start Holdings - The fund's top holdings include: 1. Longi Green Energy: -7.35% 2. Foster: -6.08% 3. Zhongyou Technology: -2.11% 4. Yinke Co.: -0.74% 5. Xinyi Solar: -4.27% - The fund has a concentration of 47.27% in its top ten holdings, focusing on the renewable energy sector, and has underperformed the market [8]

Market Overview - The Shanghai Composite Index experienced a slight decline of 0.07%, closing at 4000.14 points, while the Shenzhen Component Index fell by 0.36% to 13240.62 points, and the ChiNext Index decreased by 0.39% to 3122.03 points. In contrast, the SSE 50 Index rose by 0.32% [1] - The total trading volume across the Shanghai, Shenzhen, and Beijing markets reached 196.5 billion yuan [1] Sector Performance - Sectors such as brokerage, automotive, coal, semiconductor, chemical, and steel saw declines, while insurance, oil, and pharmaceuticals experienced gains. Notably, innovative drugs, immunotherapy, and brain engineering concepts were active [1] - The current market environment shows a divergence in preference for "policy certainty" and "high-growth elasticity," with the Shanghai Composite Index demonstrating relative resilience compared to the ChiNext Index, which is dragged down by technology stocks [1] Investment Insights - The short-term market is expected to continue a structural trend dominated by "new energy + policy themes," with photovoltaic equipment benefiting from the implementation of new energy consumption policies and technological breakthroughs, indicating potential sustained prosperity [1] - After adjustments, the technology growth sector may present rebound opportunities if there are new catalysts in semiconductor domestic substitution or AI applications, although caution is advised regarding high valuation digestion pressure [1] - A balanced investment strategy focusing on "dividend & micro-cap stocks and technology-driven sectors" is recommended. If domestic policies lead to a sustained recovery in the consumer market, there may be further investment opportunities in the consumer sector [1]

人民财讯11月12日电，今日三大指数小幅低开后震荡调整，深证成指、创业板指盘中一度跌逾1%，尾 盘再度反弹，跌幅收窄。截至收盘，沪指跌0.07%，深证成指跌0.36%，创业板指跌0.39%。盘面上，银 行板块走高，农业银行、工商银行创历史新高。石油、天然气板块走强，石化油服、准油股份、胜利股 份等涨停。免疫治疗、创新药概念走高，济民健康、中源协和、开能健康等涨停。纺织服饰板块活跃， 九牧王、七匹狼等涨停。保险、石油、银行、纺织服饰等板块涨幅居前；培育钻石、矿物制品、BC电 池、电气设备等板块跌幅居前。 ...

Group 1 - The immunotherapy sector is experiencing a strong rebound, with companies like Zhongyuan Qihuo and Kaineng Health hitting the daily limit up [1] - Other companies in the sector, such as Jimin Health, Guanhao Bio, Chengda Pharmaceutical, Zexing Pharmaceutical, and Heyuan Bio, are also showing significant gains [1]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported total revenues of approximately $598 million, including Cabozantinib franchise net product revenues of approximately $543 million, which represents a year-over-year growth of about 14% from $478 million in Q3 2024 [7][13] - Gross-to-net for the Cabozantinib franchise in Q3 2025 was 30.4%, with total operating expenses of approximately $361 million, compared to $355 million in Q2 2025 [13][14] - The company reported GAAP net income of approximately $193.6 million, or $0.72 per share basic, and non-GAAP net income of approximately $217.9 million, or $0.81 per share basic [14][15] - Cash and marketable securities at the end of Q3 2025 were approximately $1.6 billion, with share repurchases totaling approximately $99 million during the quarter [15] Business Line Data and Key Metrics Changes - The Cabozantinib U.S. business showed strong growth, with net product revenues growing to $543 million in Q3 2025, and global revenues from the Cabozantinib franchise reaching approximately $739 million [7][8] - Demand in neuroendocrine tumors grew about 50% and contributed approximately 6% of the third-quarter business, with expectations to exceed $100 million in revenue for this indication in 2025 [8][31] - The Zanzalintinib franchise is advancing with seven ongoing pivotal trials, and the company aims to file for regulatory approval in the CRC indication as soon as possible [9][10] Market Data and Key Metrics Changes - Cabozantinib maintained its leadership position as the top TKI for RCC, with a greater than 40% new patient share in the oral second-line plus net segment [7][8] - The company is expanding its GI sales team to accelerate growth in the Cabo net indication before Zanza's anticipated launch [8][34] - Market research indicates that Cabometyx is viewed as the best-in-class oral therapy in neuroendocrine tumors, which is expected to drive prescribing behavior positively [32][33] Company Strategy and Development Direction - The company is focused on building a best-in-class, multi-franchise oncology business, with a commitment to improving the standard of care for cancer patients [6][9] - There is a strong emphasis on the Zanzalintinib franchise as a potential second oncology franchise that could eclipse the size and impact of the Cabozantinib business [9][10] - The company plans to repurchase shares when undervalued and has been authorized to repurchase an additional $750 million of shares [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong performance of the Cabozantinib business and the potential of Zanzalintinib, particularly following positive trial results [6][9] - The company is optimistic about the upcoming NDA filing for Zanzalintinib and the potential for a broad label in CRC, which could significantly enhance its market position [10][73] - Management highlighted the importance of navigating the competitive landscape effectively, especially with the anticipated launch of Zanzalintinib [9][10] Other Important Information - Susan Hubbard, EVP of Public Affairs and Investor Relations, announced her retirement, with Andrew Peters set to take over her responsibilities [38][39] - The company is preparing for an R&D day on December 10th, where more details on the early-stage pipeline and Zanzalintinib trials will be shared [12][27] Q&A Session Summary Question: Can you summarize the post-ESMO feedback on Zanzalintinib results? - Management noted positive feedback from physicians regarding the overall survival benefit and the potential for Zanzalintinib to capture market share in a fragmented market [42][44] Question: Why is Sunitinib the right control for STELLAR-304? - Management explained that Sunitinib is a standard of care in the setting and has a relevant target profile, making it a suitable comparator for the trial [48][50] Question: How does the STELLAR-303 data set expectations for the NLM cut? - Management indicated that the trial was designed to include both liver and non-liver metastases, with results expected to mature around mid-year 2026 [52][55] Question: What is the strategy regarding potential cannibalization between Cabozantinib and Zanzalintinib? - Management expressed confidence in the distinct positioning of Zanzalintinib in the market, emphasizing the growth potential for both products [67][70] Question: Will the NDA submission for Zanzalintinib include both subgroups? - Management confirmed that the NDA will be filed based on the ITT population, which encompasses the entire trial population, allowing for a broad label [72][73]

Financial Data and Key Metrics Changes - The company reported total revenues of approximately $598 million for Q3 2025, which included Cabozantinib franchise net product revenues of approximately $543 million, reflecting a year-over-year growth of about 14% from $478 million in Q3 2024 [7][13] - Non-GAAP net income for Q3 2025 was approximately $217.9 million, or $0.81 per share basic, compared to $193.6 million GAAP net income, or $0.72 per share basic [14][15] - Cash and marketable securities at the end of Q3 2025 were approximately $1.6 billion, with share repurchases totaling approximately $99 million during the quarter [15][16] Business Line Data and Key Metrics Changes - The Cabozantinib business maintained its leadership position as the top TKI for RCC, with net product revenues growing to approximately $543 million in Q3 2025 [7][28] - Demand in neuroendocrine tumors grew about 50% quarter-over-quarter, contributing approximately 6% of total demand for Cabozantinib in Q3 2025 [8][31] - The company expects to exceed $100 million in revenue for the neuroendocrine tumor indication in 2025 [8][32] Market Data and Key Metrics Changes - The Cabozantinib franchise net product revenues generated globally were approximately $739 million in Q3 2025, compared to $653 million in Q3 2024 [7] - Cabometyx's TRX volume grew 21% in Q3 2025 relative to Q3 2024, outpacing the market basket growth rate of 13% [29] - Cabometyx achieved a new patient market share of over 40% in the second-line plus neuroendocrine tumors segment [31] Company Strategy and Development Direction - The company aims to build a best-in-class, multi-franchise oncology business, focusing on improving the standard of care for cancer patients [6] - Zanzalintinib is positioned as the next oncology franchise opportunity, with seven ongoing and soon-to-start pivotal trials [9][12] - The company plans to expedite the build-out of its GI sales team to support the growth of the Cabozantinib neuroendocrine tumor indication and prepare for Zanzalintinib's launch [8][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong performance of the Cabozantinib business and the potential of Zanzalintinib to eclipse it [6][9] - The company is optimistic about the regulatory approval process for Zanzalintinib, especially following positive results from the Stellar-303 trial [10][20] - Management highlighted the importance of capital allocation and plans to repurchase shares when undervalued, with an additional $750 million share repurchase program authorized [12][15] Other Important Information - Susan Hubbard, EVP of Public Affairs and Investor Relations, announced her retirement after more than 35 years in the biopharma industry [38] - Andrew Peters will take over investor relations responsibilities, reflecting a strategic move within the company [39] Q&A Session Summary Question: Can you summarize the post-ESMO feedback on Zanzalintinib results? - Management noted positive feedback from physicians regarding the overall survival benefit and the introduction of an immune checkpoint inhibitor in a significant tumor type [41][43] Question: Why is Sunitinib the right control for the Stellar-304 study? - Management explained that Sunitinib is a standard of care in the setting and has a relevant target profile, making it a suitable comparator [47][49] Question: How does the Stellar-303 initial data set expectations for the NLM cut? - Management indicated that the study's design allowed for a broader analysis, and they expect results for the non-liver metastases subgroup to mature around mid-year 2026 [51][54] Question: What is the clinical trial contribution for Cabozantinib in Q3? - There were no clinical trial sales reported in the quarter [58] Question: Is there a risk to the Stellar-303 trial approval? - Management refrained from commenting on external opinions regarding Cabozantinib's usefulness [62] Question: How is the NET launch performing relative to Lutathera? - Management expressed confidence in the strong performance of Cabozantinib in the NET market, indicating a favorable position compared to Lutathera [85]

Core Insights - Shanghai Junshi Biosciences Co., Ltd. (复宏汉霖) announced key updates on its investigational product HLX43, a PD-L1 targeted antibody-drug conjugate for non-small cell lung cancer (NSCLC) treatment at the 2025 International Lung Cancer Frontier and Innovation Forum [1] - HLX43 has received orphan drug designation from the FDA for thymic epithelial tumors, indicating its potential in treating advanced/metastatic solid tumors [1] - The company plans to initiate at least eight Phase III clinical trials for HLX43, with lung cancer indications prioritized [1] Company Developments - CEO Dr. Zhu Jun emphasized the commitment to developing HLX43 despite limited resources, highlighting lung cancer as the leading malignancy in both global and Chinese contexts [2] - Junshi has successfully launched nine products globally, including the first approved PD-1 monoclonal antibody for first-line treatment of small cell lung cancer [2] - Goldman Sachs issued a research report covering Junshi, projecting HLX43 as a core driver for the company's global innovation pipeline and assigning a "buy" rating with a 12-month target price of HKD 100.70 per share [2] Clinical Data - As of October 22, 2025, 174 advanced NSCLC patients were enrolled in the study, with 89 receiving 2.0 mg/kg and 85 receiving 2.5 mg/kg of HLX43 [3] - The overall efficacy of HLX43 was promising, with an objective response rate (ORR) of 33.3% and a disease control rate (DCR) of 75.8% in squamous NSCLC patients [3] - In non-squamous patients, the ORR increased to 48.6% and the DCR reached 94.3% [3] Treatment Potential - Among previously treated squamous NSCLC patients who had undergone docetaxel therapy, the ORR was 38.5% and the DCR was 84.6%, indicating HLX43's significant potential in this population [4] - Docetaxel is currently the standard second-line treatment for squamous NSCLC, with an ORR slightly above 10%, suggesting HLX43 may redefine treatment standards for this disease [4]